Healthcare Industry News: Uveitis
News Release - July 25, 2007
EyeGate Pharma Announces Executive Appointments
WALTHAM, MA,--(Healthcare Sales & Marketing Network)--Jul 25, 2007 -- EyeGate Pharma, a privately held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced the appointment of Michael A. Patane, Ph.D., as Vice President of Research and Development and the promotion of Michael P. Manzo to Vice President of Engineering.Stephen From, President and Chief Executive Officer of EyeGate Pharma, commented, "Dr. Patane brings a wealth of pharmaceutical research and development expertise to EyeGate. His demonstrated ability to manage complex drug discovery programs and his proven drug development track record will be great assets as we progress the EyeGate® II Delivery System into clinical development to treat severe Uveitis in 2008."
Mr. From continued, "During his tenure with EyeGate, Michael Manzo has made remarkable contributions and helped to create a culture of engineering and operational excellence. His continued leadership will be instrumental to the future success of the company."
Michael A. Patane, Ph.D., brings to EyeGate more than ten years of drug discovery experience with leading pharmaceutical and biotechnology organizations. Most recently, Dr. Patane was Executive Director, Global Discovery Chemistry, at the Novartis Institutes for BioMedical Research, where he was responsible for infectious diseases and ophthalmology drug discovery programs. Previously, Dr. Patane was Director, Medicinal Chemistry at Millennium Pharmaceuticals, Inc., where he led drug discovery efforts for multiple oncology and metabolic disease research programs.
Earlier in his career, Dr. Patane was a Research Fellow in Medicinal Chemistry at Merck & Co. He earned a B.S. in Chemistry from Fordham University, a Ph.D. in Synthetic Organic Chemistry from the University of Southern California, and completed his post-doctoral studies in Synthetic, Natural Products, and Medicinal Chemistry at The Scripps Research Institute.
Michael Manzo joined EyeGate in the fall of 2006 as Senior Director of Engineering, a role in which he has excelled. Previously, he was President and Chief Operating Officer of Jenline Industries, a developer of silicone-based products used in optics, medical electronics, healthcare and telecommunications. At Jenline, he was responsible for overseeing financial, engineering, manufacturing and quality control functions.
Prior to Jenline, Mr. Manzo served as Senior Marketing Engineer at ONUX Medical, where he developed contractual partnerships with clinicians, medical institutions and laboratory facilities and worked with the marketing department to assess market needs. Mr. Manzo earned a B.S. in Plastics Engineering from the University of Lowell and an MBA from Suffolk University.
About EyeGate Pharma
EyeGate Pharma was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (across the sclera, or white protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was designed by ophthalmologists for ophthalmologists. This non-invasive system can be applied to safely deliver a wide range of therapeutics to both the anterior and posterior chambers of the eye. An 89-patient pilot study, using the Company's first-generation delivery device, demonstrated exceptional patient tolerance with a significant decrease in inflammatory markers and a concurrent increase in visual acuity. A typical application takes less than five minutes and has been shown to be extremely well tolerated in patients suffering from severe Uveitis and other inflammatory ocular diseases. Clinical studies utilizing the EyeGate® II Delivery System are scheduled to begin in the first half of 2008. For more information please visit www.eyegatepharma.com.
Source: EyeGate Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
